Helex

Helex is a therapeutics company developing a new class of targeted genetic medicines for kidney diseases using proprietary non-viral lipid nanoparticle (LNP) drug delivery and AI-based drug design platforms. The company's lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), which affects more than 12 million people worldwide, by enabling programmable delivery of genome-editing cargo directly to kidney cells — long considered one of the hardest challenges in drug delivery. Founded in 2021 and backed by SOSV's IndieBio program, Helex operates from New York and Hyderabad, India, with the goal of making disease-modifying renal therapies accessible and affordable.